Shaobo Ke
Overview
Explore the profile of Shaobo Ke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, Wang J, Shi W, Qiu H, Ke S, Tian Y, et al.
Mol Cancer Ther
. 2025 Feb;
PMID: 39895587
In this prospective, open-label, exploratory study (RENMIN-213), patients with previously untreated, HER2-negative, advanced G/GEJ adenocarcinoma patients with signet ring cell carcinoma or peritoneal metastasis, were enrolled to receive 8 cycles...
2.
Qiu H, Gao L, Shi W, Wang J, Li B, Ke S, et al.
Cancer Lett
. 2024 Dec;
611:217401.
PMID: 39694222
Elaiophylin is known to exert antitumor effects through certain signaling pathways; however, no reports regarding its effects on esophageal cancer are available. This study explored the effects of elaiophylin in...
3.
Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, et al.
EClinicalMedicine
. 2023 Nov;
66:102315.
PMID: 38024475
Background: Immunotherapy has revolutionized the treatment of cancer. However, microsatellite stable (MSS) metastatic colorectal cancer (mCRC) shows a low response to PD-1 inhibitors. Antiangiogenic therapy can enhance anti-PD-1 efficacy, but...
4.
Tian Y, Shi Z, Wang C, Ke S, Qiu H, Zhao W, et al.
Ann Surg Oncol
. 2023 Nov;
31(2):860-871.
PMID: 37947979
Background: Neoadjuvant chemoradiotherapy (NCRT) is recommended as the treatment standard for locally advanced esophageal squamous cell carcinoma (ESCC). The use of immunotherapy in the neoadjuvant setting has gained attention. Multiple,...
5.
Fan X, Wang J, Xia L, Qiu H, Tian Y, Zhangcai Y, et al.
Int J Surg
. 2023 May;
109(6):1708-1719.
PMID: 37132192
Background: The efficacy of endoscopic therapy on the long-term survival outcomes of T1b oesophageal cancer (EC) is unclear, this study was designed to clarify the survival outcomes of endoscopic therapy...
6.
Zhao W, Ke S, Cai X, Zuo Z, Shi W, Qiu H, et al.
Radiother Oncol
. 2023 Apr;
184:109679.
PMID: 37105302
Background And Purpose: Immunotherapy has revolutionized the treatment of advanced and metastatic esophageal squamous cell carcinoma (ESCC), but most patients eventually developed disease progression. Immuno-resistance is becoming an unavoidable clinical...
7.
Chen Y, Wu X, Hao D, Cheng X, Zhang L, Zhang Y, et al.
Oncotarget
. 2022 Dec;
13:1300.
PMID: 36473119
No abstract available.
8.
Shi Z, Zhu X, Ruan C, Wei G, Li J, Qiu H, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2244619.
PMID: 36454568
Importance: The optimal treatment for and potential benefit populations of synchronous oligometastatic esophageal squamous cell carcinoma (SOESCC) remain unclear. Objectives: To evaluate outcomes of concurrent chemoradiotherapy (CCRT) and to construct...
9.
Qiu H, Ke S, Cai G, Wu Y, Wang J, Shi W, et al.
Cancer Med
. 2022 May;
12(1):213-222.
PMID: 35633045
Purpose: To evaluate the clinical efficacy and safety of apatinib combined with intensity-modulated radiation therapy (IMRT) in patients with unresectable hepatocellular carcinoma (uHCC). Materials And Methods: Open-label, single-arm, exploratory clinical...
10.
Chen J, Luo B, Gao M, Cai G, Luo X, Zhang-Cai Y, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626205
Microinvasive breast cancer (MBC for short) is a rare entity with the decision of axillary surgery under debate in clinical practice. We aimed to unravel the lymph node metastasis (LNM)...